Every Form 4 that XOMA Royalty Corporation (XOMAP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XOMAP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XOMAP filings page.
BVF-affiliated funds and accounts reported tendering an aggregate 7,593,303 shares of XOMA Royalty Corp common stock on July 14, 2026, in dispositions pursuant to Ligand Pharmaceuticals’ cash merger. The reporting persons received $39.00 in cash per share plus contingent value rights and report no remaining holdings for these positions.
Montano Maricel Perea reported disposition transactions in this Form 4 filing.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, reported equity changes tied to its merger with Ligand Pharmaceuticals. Common stock totaling 42,371 shares (42,306 held directly and 65 via a 401(k) plan) was reclassified in a holding company reorganization, and she now reports no common share holdings. In connection with the same Merger Agreement, 11,316 and 37,074 performance stock units were cancelled and converted into the right to receive $39.00 in cash per underlying share plus contingent value rights.
XOMA Royalty Corp director Joseph M. Limber reported the disposition of all his reported securities in connection with a merger involving Ligand Pharmaceuticals. His 9,532 common shares converted into the right to receive $39.00 per share in cash plus contingent value rights, while 8.625% Series A and 8.375% Series B preferred shares were redeemed. Multiple stock option grants were either exchanged for cash plus CVRs or canceled with no consideration under the Merger Agreement, leaving him with no remaining XOMA holdings.
XOMA Royalty Corp director Barbara Kosacz reported equity changes tied to the July 14, 2026 merger with Ligand Pharmaceuticals. Her 6,269 common shares were converted into the right to receive merger consideration that includes $39.00 per share in cash and contingent value rights, as described in the merger agreement. In addition, multiple stock options with exercise prices such as $24.7100, $21.3900, $17.8600, $31.0400, $21.2700, $15.5900 and $12.6500 per share were cancelled and disposed of to the issuer in connection with the transaction. After these actions, the report shows she directly holds no common shares or listed stock options.
WYSZOMIERSKI JACK L reported disposition transactions in this Form 4 filing.
XOMA Royalty Corp director Jack L. Wyszomierski reported the conversion of 21,828 common shares in connection with XOMA's merger with Ligand Pharmaceuticals. Each share converted into the right to receive $39.00 in cash plus contingent value rights, and all reported stock options were cancelled under the merger agreement, leaving him with 0 XOMA common shares or options.
Owen Hughes, Chief Executive Officer of XOMA Royalty Corp, reported multiple equity dispositions associated with the completion of XOMA’s merger with Ligand Pharmaceuticals. He disposed of 102,000 depositary shares of 8.375% Series B cumulative preferred stock, common stock positions, performance stock units and stock options back to the issuer, leaving no reported XOMA holdings in these securities after July 14, 2026. Under the merger terms, each common share converted into the right to receive $39.00 in cash plus contingent value rights, while preferred shares were redeemed with accrued and unpaid dividends and equity awards were either cashed out or cancelled in exchange for cash and contingent value rights.
Natasha Hernday, a director of XOMA Royalty Corp, reported dispositions and restructuring of her equity in connection with XOMA’s merger with Ligand Pharmaceuticals. She reported the disposition of 4,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock and a restructuring transaction involving 9,304 common shares, after which she reported holding zero common shares and preferred shares. She also reported issuer dispositions of multiple stock options covering tens of thousands of underlying common shares. Under the merger terms, each common share generally converted into the right to receive $39.00 in cash per share plus contingent value rights, while preferred shares were redeemed with accrued dividends and certain stock options were either cashed out for cash plus contingent value rights or cancelled with no consideration.
XOMA Royalty Corp Chief Investment Officer Bradley Sitko reported merger-related dispositions and restructurings of his equity and award holdings. In connection with Ligand Pharmaceuticals’ acquisition, his common stock, preferred shares, options and stock units were cancelled, redeemed or converted into $39.00 per share in cash plus contingent value rights, leaving no reported post-transaction holdings in these securities.
XOMA Royalty Corp director Matthew D. Perry reported the cancellation and disposition of his equity in connection with a merger with Ligand Pharmaceuticals Incorporated. A total of 24,138 shares of common stock were disposed of in a holding company reorganization, and several stock options with exercise prices ranging from $4.67 to $31.04 per share were cancelled or surrendered to the issuer. At the merger’s effective time, each common share converted into the right to receive $39.00 in cash per share plus contingent value rights, and in-the-money options were exchanged for cash based on the spread over $39.00 plus one contingent value right per underlying share, leaving Perry with no reported remaining holdings.
XOMA Royalty Corp Chief Financial Officer Jeffrey Trigilio reported the disposition of his equity in connection with the merger of XOMA Royalty with an affiliate of Ligand Pharmaceuticals Incorporated. On July 14, 2026, 103,906 shares of common stock and all reported performance stock units were eliminated, leaving him with 0 shares and 0 derivative units.
Under the Merger Agreement, each share of common stock automatically converted at the effective time into the right to receive $39.00 per share in cash, subject to withholding, plus contingent value rights representing potential future contingent payments. Outstanding RSUs and performance stock unit awards vested or were converted and then cancelled for cash based on the $39.00 Closing Amount per underlying share and one contingent value right for each such share.
XOMA Royalty Corp director Heather L. Franklin reported disposition of 6,269 shares of common stock and cancellation of several stock option awards on July 14, 2026, in connection with the merger between XOMA Royalty Corporation and Ligand Pharmaceuticals. At the merger’s Effective Time, each share of XOMA common stock converted into the right to receive $39.00 per share in cash plus contingent value rights (CVRs), subject to withholding taxes. Restricted stock units and certain company stock options became fully vested, were cancelled, and exchanged for cash based on the Closing Amount plus one CVR per underlying share. After these transactions, the holdings reported here show zero remaining shares and options for Franklin.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Jack L. Wyszomierski received an equity grant in the form of restricted stock units. He was awarded 3,586 RSUs, each representing one share of common stock at settlement. Following the grant, he directly holds 25,116 shares of common stock.
The 3,586 RSUs vest in equal monthly installments over 12 months from the grant date, conditioned on his continued service with the company. This compensation-related award is not an open-market purchase or sale but a stock-based incentive.
LIMBER JOSEPH M reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Joseph M. Limber received a grant of 3,586 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents one share of common stock and will vest in equal monthly installments over 12 months from the grant date, subject to his continued service.
Following the grant, Limber directly holds 12,820 shares of common stock. He also reports direct holdings of 10,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock and 20,000 Depositary Shares representing 8.375% Series B Cumulative stock.
XOMA Royalty Corp director Natasha Hernday received an equity grant of 3,586 restricted stock units (RSUs) of common stock. The grant has a stated price of $0.00 per share and is described as a compensation-related award rather than an open-market purchase.
Each RSU converts into one share of XOMA common stock upon settlement and will vest in equal monthly installments over 12 months from the grant date, contingent on Hernday’s continued service. Following this grant, she directly holds 12,592 shares of common stock and 4,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock.
XOMA Royalty Corp director Matthew D. Perry received a grant of 3,586 restricted stock units (RSUs) of common stock at no cost. Each RSU converts into one share and will vest in equal monthly installments over 12 months, contingent on his continued service. Following this equity award, he directly owns 27,426 shares of XOMA common stock.
Franklin Heather L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Heather L. Franklin received a grant of 3,586 restricted stock units (RSUs) of common stock on May 21, 2026. The award was made at no cash cost per share as part of equity compensation. Each RSU represents the right to receive one share of XOMA common stock at settlement and will vest in equal monthly installments over 12 months, subject to her continued service with the company. Following this grant, Franklin directly owns 9,557 shares of common stock, reflecting a modest, routine increase in her equity stake through compensation rather than open‑market buying.
Kosacz Barbara reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Barbara Kosacz received a grant of 3,586 restricted stock units (RSUs) of common stock. The RSUs were awarded at no cash cost per unit and will vest in equal monthly installments over 12 months, conditioned on her continued service to the company. Following this equity award, she holds 9,557 shares of common stock directly.
XOMA Royalty Corp large shareholders affiliated with Biotechnology Value Fund converted Series X Convertible Preferred Stock into common stock. On May 14, 2026, entities in the reporting group converted a total of 5,003 shares of Series X Preferred into 5,003,000 shares of common stock at a $4.03 per share conversion price. After these conversions, the Form 4 shows only common stock positions, with the Series X Preferred balances reduced to zero for the reporting entities involved. The transactions are reported as exempt from short-swing profit rules under Rule 16b-6(b) and reflect changes in the form of ownership rather than open-market buying or selling.
XOMA Royalty Corp’s Chief Financial Officer, Jeffrey Trigilio, exercised Performance Stock Units into common shares. On April 20, 2026, 11,538 PSUs converted into 11,538 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Trigilio directly held 103,906 shares of common stock and 126,924 Performance Stock Units. Each PSU represents a contingent right to receive one share of common stock, vesting only if the stock reaches specified price targets and he continues serving the company through each vesting date.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, exercised performance-based equity awards into common stock. On April 20, 2026, she converted 3,370 Performance Stock Units (PSUs) into 3,370 shares of common stock at a stated price of $0.00 per share.
Following the transaction, she directly holds 41,793 common shares. The PSU award was tied to XOMA’s share price, with each PSU representing a contingent right to one share that vests only if the stock reaches specified price levels and she continues in service. After this exercise, 37,074 PSUs remain outstanding for her, scheduled to expire on March 11, 2029.
XOMA Royalty Corp director and CEO Owen Hughes reported equity compensation activity and updated holdings. On April 20, 2026, he exercised 10,568 Performance Stock Units, receiving an equal number of shares of XOMA common stock at a stated price of $0.00 per share.
Following this transaction, he holds 191,264 shares of common stock directly and 295 shares of common stock indirectly through a 401(k) plan. He also reports 102,000 depositary shares of 8.375% Series B cumulative preferred stock and a remaining balance of 116,245 Performance Stock Units, each tied to future vesting based on stock price and continued service.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.
XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.
To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director and Chief Executive Officer Owen Hughes reported new equity awards. On March 16, 2026, he received 126,813 Performance Stock Units, each representing a contingent right to one share of common stock, which vest only if the stock reaches specified price targets and he remains in service.
He was also granted 82,428 restricted stock units payable solely in common stock. These RSUs vest in four equal 25% installments on each of the first four anniversaries of March 11, 2026, subject to continued service. Following these awards, he holds 180,696 common shares directly, 295 common shares indirectly via a 401(k) plan, and 102,000 depositary shares of 8.375% Series B cumulative stock.
Bradley Sitko, Chief Investment Officer and director of XOMA Royalty Corp (XOMAP), reported transactions dated 09/19/2025. The filing shows Sitko acquired 6,712 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock; these PSUs vest upon the common stock reaching a specified price and are scheduled to be exercisable by 05/18/2026. Following the reported PSU acquisition, Sitko beneficially owned 23,488 derivative-backed shares and 19,822 common shares by direct ownership. The report also discloses disposals of certain preferred and depositary share instruments and multiple indirect holdings through his 401(k) plan, spouse, and children.
Owen Hughes, who is listed as Chief Executive Officer and a Director of XOMA Royalty Corp, reported transactions dated 09/19/2025. The filing shows acquisition of 35,567 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock and vest upon the common stock reaching a specified price per share. After these derivative and related non‑derivative entries, Mr. Hughes is reported to beneficially own 132,714 shares on a direct basis. The filing also records a disposition of 2,000 Depository Shares of an 8.375% Series B Cumulative security. The form is signed by an attorney‑in‑fact and includes a Power of Attorney exhibit.
Thomas M. Burns, SVP, Finance & CFO of XOMA Royalty Corp (symbol: XOMAP), reported equity activity related to vested performance stock units and subsequent share sales to cover taxes. He was credited with 11,846 common shares from PSUs that vest when the stock reaches a specified price, increasing his direct common-stock holdings to 34,409 shares. Shortly thereafter he sold 4,300 shares at $35.98 and two small blocks of 15 shares each at $36.93 and $36.81, reducing his direct holdings to roughly 30,079 shares.
He also reports 6,130 shares held indirectly through a 401(k) plan and disposal of 2,000 depository shares and 2,000 series A preferred shares. The filing explains the sales were to satisfy tax withholding on PSU settlement, and the PSUs convert one-for-one into common stock with an exercisable date of 05/18/2026.
Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.